Categories: BrainNews

AmblyoPlay Launches New Technology for Greater Peripheral Vision Stimulation

Idrija, Slovenia–(Newsfile Corp. – October 15, 2024) – AmblyoPlay, a leading innovator in vision therapy solutions, proudly announces the launch of its revolutionary technology: Active Peripheral Stimulation(APS). APS, which is intended to advance the treatment of peripheral vision deficiencies, is a significant step towards improving the effectiveness of home-based vision therapy.

Active peripheral stimulation example in exercises.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10919/226582_689a718354061883_001full.jpg

APS technology, available within the existing AmblyoPlay Vision Therapy, is tailored to improve peripheral vision by actively engaging and stimulating the peripheral areas of the retina. This unique approach improves the brain’s ability to integrate peripheral inputs, resulting in increased spatial awareness.

While amblyopia (often referred to as “lazy eye”) may sound like a very niche problem, up to 5% of the population suffer from this vision disorder worldwide. Nonetheless, it remains a substantial global vision problem, and public health initiatives of early screening, treatment, and management are critical.

Normal versus amblyopic eye.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10919/226582_689a718354061883_002full.jpg

People with amblyopia and other binocular vision problems often struggle with depth perception, hand-eye coordination, and reading difficulties and may experience frustration or lower self-esteem due to challenges in everyday tasks like driving, sports, and learning.

AmblyoPlay raises the bar for treating amblyopia, strabismus, convergence insufficiency, and other visual impairments by incorporating APS technology within vision therapy. The technology has been seamlessly incorporated into therapeutic exercises, ensuring a smooth and engaging experience for users of all ages.

“With APS, we’re expanding the boundaries of what vision therapy can achieve,” said Matic Vogrič, CEO of AmblyoPlay.

About AmblyoPlay Vision Therapy

AmblyoPlay was born from conversations with doctors and parents, all facing a common challenge: how to keep young patients motivated during vision therapy homework. Existing solutions were repetitive and disengaging, leading to frustration. Therefore, AmblyoPlay transformed vision therapy into a gamified experience-turning a routine task into something fun.

This playful approach not only keeps patients engaged but also improves adherence to therapy, helping families and doctors work together toward better vision outcomes.

AmblyoPlay is a vision therapy solution designed to treat vision impairments such as amblyopia (lazy eye), strabismus (crossed eyes), convergence insufficiency, double vision, and other binocular vision disorders. It complements in-office vision therapy and increases at-home vision therapy adherence through gamification.

By offering personalized and evidence-based therapy, AmblyoPlay provides effective solutions for children and adults alike, bringing engaging therapy into the comfort of users’ homes.

Until now, it has helped more than 25.000 users worldwide. Discover more about AmblyoPlay at https://amblyoplay.com/ or watch the video.

Discover more about AmblyoPlay
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10919/226582_689a718354061883_003full.jpg

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10919/226582_689a718354061883_004full.jpg

Contact Information

Matic Vogrič, CEO
matic.vogric@amblyoplay.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226582

Staff

Recent Posts

Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle

Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…

2 days ago

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

2 days ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

2 days ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

2 days ago